Relay Therapeutics, Inc. Common Stock (RLAY) News
Latest headlines that mention RLAY, newest first · each headline opens the original publisher
- Last price
- $17.41
- Day change
- -3.01%
- Next earnings
- 2026-11-05
RLAY headlines
latest coverageCatinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains. The post This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion appeared first on Investor's Business Daily .
This precision oncology innovator, up nearly 500% in a year, just reported significant insider selling amid ongoing drug development efforts.
Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.
In a way, this was a delayed reaction to excellent news from the lab.
Relay Therapeutics wiped the floor Tuesday with Wall Street's expectations for its experimental vascular anomalies treatment. The post This Biotech's Drug Just Wiped The Floor With Forecasts appeared first on Investor's Business Daily .
RLAY news alerts
Get an alert by email or push when a new headline mentions RLAY.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.